Canagliflozin plus chemotherapy for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding the diabetes drug canagliflozin to a standard chemotherapy medicine (gemcitabine) can help treat advanced pancreatic cancer. The goal is to see if this combination can shrink tumors or improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your pancreatic cancer must have spread to other organs (metastatic) or be too advanced to remove with surgery (unresectable).
- You are expected to live longer than 3 months.
- If you've had chemotherapy before, your last treatment ended more than a month ago. Or you haven't had chemo yet.
- You should be able to take care of yourself (ability to do daily tasks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving extra diabetes medication along with standard chemotherapy can help control blood sugar and improve outcomes in people with pancreatic cancer that has spread. It may help you manage diabetes better during treatment.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a new combination of three drugs for a type of pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body. The goal is to see if this combination can shrink or slow the cancer better than the current standard therapy.
This trial tests adding sitagliptin (a diabetes drug) to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread or cannot be removed by surgery. The goal is to see if the combination works better than chemo alone.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.